Duchenne Muscular Dystrophy Drugs Market Report 2026

The duchenne muscular dystrophy drugs market size has grown rapidly in recent years. It will grow from $3.2 billion in 2025 to $3.64 billion in 2026 at a compound annual growth rate (CAGR) of 13.5%. The growth in the historic period can be attributed to limited treatment options, increasing awareness of dmd, growing pediatric patient population, adoption of corticosteroids, early-stage r&d in gene therapy.

The duchenne muscular dystrophy drugs market size is expected to see rapid growth in the next few years. It will grow to $6.01 billion in 2030 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to advancements in exon skipping drugs, innovations in gene editing technologies, increasing government and regulatory support, rising investment in rare disease therapies, expansion of specialty care and hospital networks. Major trends in the forecast period include rising adoption of exon skipping therapies, increasing use of gene therapy approaches for dmd, growing preference for injectable and targeted drug delivery, expansion of online and hospital pharmacy distribution channels, development of supportive therapies such as myostatin inhibitors and utrophin modulators.

The expansion of personalized medicine is expected to drive the growth of the Duchenne muscular dystrophy (DMD) drugs market in the coming years. Personalized medicine is a healthcare approach that customizes treatments for individual patients based on their genetic makeup, environmental influences, and lifestyle factors to achieve better clinical outcomes. The increasing adoption of personalized medicine is largely driven by advancements in genomic technologies, which allow for the accurate identification of genetic variations and the development of tailored therapies. In the context of Duchenne muscular dystrophy, personalized medicine supports the development of targeted treatments aligned with specific genetic mutations, improving drug effectiveness and overall patient care. It also enhances drug development by concentrating on mutation-specific therapies, leading to improved treatment outcomes. For example, in February 2024, according to the Personalized Medicine Coalition (PMC), a U.S.-based nonprofit organization, the U.S. Food and Drug Administration approved 26 new personalized medicines in 2023, a notable rise from 12 approvals in 2022. Therefore, the growth of personalized medicine is contributing to the expansion of the Duchenne muscular dystrophy drugs market.

Major companies operating in the Duchenne muscular dystrophy drugs market are concentrating on the development of innovative treatment options, such as corticosteroids, to improve muscle strength, slow disease progression, and enhance overall patient outcomes. Corticosteroids are steroid-based medications, either naturally produced by the adrenal glands or synthetically manufactured, that help reduce inflammation and regulate immune responses. For instance, in March 2024, Catalyst Pharmaceuticals, a U.S.-based biopharmaceutical company, launched AGAMREE (vamorolone) oral suspension 40 mg/mL, an FDA-approved treatment for Duchenne muscular dystrophy in patients aged two years and older. AGAMREE is a corticosteroid that reduces inflammation and stabilizes muscle cell membranes, thereby helping to slow the progression of the disease.

In July 2023, Catalyst Pharmaceuticals, a U.S.-based biopharmaceutical company, acquired the exclusive North American license for vamorolone (AGAMREE), a Duchenne muscular dystrophy drug, from Santhera Pharmaceuticals for an undisclosed amount. Through this acquisition, Catalyst Pharmaceuticals aimed to strengthen its Duchenne muscular dystrophy portfolio by offering a safer and more effective treatment option and addressing the growing demand for targeted therapies for DMD patients. Santhera Pharmaceuticals is a Switzerland-based pharmaceutical company focused on developing innovative treatments for Duchenne muscular dystrophy.

Major companies operating in the duchenne muscular dystrophy drugs market are Pfizer Inc, Sanofi S.A, Novartis AG, Italfarmaco S.p.A, Sarepta Therapeutics Inc, PTC Therapeutics Inc, FibroGen Inc, Wave Life Sciences Ltd, Solid Biosciences Inc, NS Pharma, Capricor Therapeutics Inc, Santhera Pharmaceuticals, ReveraGen BioPharma, Antisense Therapeutics Limited, Catalyst Pharmaceuticals Inc, EspeRare Foundation, Cure Rare Disease, Akashi Therapeutics Inc, BioMarin Pharmaceutical Inc, Daiichi Sankyo Co Ltd, Nippon Shinyaku Co Ltd, Regenxbio Inc, Ultragenyx Pharmaceutical Inc, Dyne Therapeutics Inc, Entrada Therapeutics Inc.

North America was the largest region in the duchenne muscular dystrophy (DMD) drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the duchenne muscular dystrophy drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the duchenne muscular dystrophy drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the duchenne muscular dystrophy drugs market by increasing the cost of imported gene therapies, exon skipping drugs, and corticosteroids, which has led to higher treatment costs. Hospital pharmacies and specialty drug segments in regions like North America and Europe are particularly affected due to reliance on imported therapies. While tariffs may temporarily limit accessibility and slow market growth, they also promote local manufacturing initiatives and encourage the development of cost-effective domestic therapies, supporting long-term market resilience.

The duchenne muscular dystrophy drugs market research report is one of a series of new reports that provides duchenne muscular dystrophy drugs market statistics, including duchenne muscular dystrophy drugs industry global market size, regional shares, competitors with a duchenne muscular dystrophy drugs market share, detailed duchenne muscular dystrophy drugs market segments, market trends and opportunities, and any further data you may need to thrive in the duchenne muscular dystrophy drugs industry. This duchenne muscular dystrophy drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Duchenne muscular dystrophy (DMD) drugs are medications and therapies designed to manage and slow the progression of Duchenne muscular dystrophy, a genetic disorder that leads to muscle weakness and degeneration. These drugs target the underlying genetic mutations, improve muscle function, and enhance quality of life. The primary goal of these drugs is to preserve muscle strength, delay disease progression, and increase mobility in individuals with DMD.

The main types of drugs in the duchenne muscular dystrophy market include exon skipping drugs, corticosteroids, gene therapy, and other treatments. Exon skipping drugs are specialized therapies that enable the body to produce a functional, albeit shorter, version of the dystrophin protein by bypassing defective sections of the dystrophin gene during protein synthesis. These drugs are administered through oral and injectable routes, and they are distributed via several channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The Duchenne muscular dystrophy (DMD) drugs market consists of sales of utrophin modulators, anti-inflammatory agents and myostatin inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.